

Gary S Gottesman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2539281/publications.pdf>

Version: 2024-02-01

10
papers

539
citations

1163117

8
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

564
citing authors

#	ARTICLE	IF	CITATIONS
1	Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 2416-2427.	13.7	229
2	Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 189-199.	11.4	115
3	New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6. <i>Bone</i> , 2019, 127, 228-243.	2.9	42
4	Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS. <i>Bone</i> , 2017, 101, 145-155.	2.9	37
5	Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3241-e3253.	3.6	36
6	Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. <i>Calcified Tissue International</i> , 2021, 108, 622-633.	3.1	26
7	Gnathodiaphyseal dysplasia: Severe atypical presentation with novel heterozygous mutation of the anoctamin gene (ANO5). <i>Bone</i> , 2018, 107, 161-171.	2.9	23
8	Auricular ossification: A newly recognized feature of osteoprotegerin deficiency juvenile Paget disease. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 978-985.	1.2	11
9	Health Care Transition From Pediatric- to Adult-Focused Care in X-linked Hypophosphatemia: Expert Consensus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 599-613.	3.6	11
10	Unique Variant of <i>NOD2</i> Pediatric Granulomatous Arthritis With Severe 1,25-Dihydroxyvitamin D-Mediated Hypercalcemia and Generalized Osteosclerosis. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 2071-2080.	2.8	9